Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...

After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...

After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...

Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem cell-based therapy to treat severe aplastic ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

While the China-targeting Biosecure Act failed to pass muster in a key defense spending bill last year, a retooled version of ...